Quarterly report [Sections 13 or 15(d)]

SCHEDULE OF RECONCILIATION OF ADJUSTED EBITDA (Details)

v3.25.3
SCHEDULE OF RECONCILIATION OF ADJUSTED EBITDA (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Segment Reporting [Abstract]        
Income from continuing operations (GAAP Basis) $ 1,011,000 $ 1,758,000 $ 2,232,000 $ 5,081,000
Depreciation and amortization 111,000 85,000 307,000 205,000
Stock-based compensation 7,000 86,000 31,000 218,000
Severance & related expense 692,000
Asset impairment - lab supplies 198,000
Taxes (benefit) expense (11,000) 4,000 7,000 12,000
Interest accretion expense 4,000 34,000
Note payable interest 30,000 141,000 156,000 514,000
Other expense/income, net 10,000 (10,000) 25,000 (40,000)
Change in fair value of note payable 105,000 404,000 87,000 445,000
Adjusted EBITDA $ 1,263,000 $ 2,472,000 $ 3,735,000 $ 6,469,000